Behind the Insights: Ep 04 GLP-1s & Suicidal Ideation, Jessica Probst, MPH & Carl Marci, MD
Impossibile aggiungere al carrello
Rimozione dalla Lista desideri non riuscita.
Non è stato possibile aggiungere il titolo alla Libreria
Non è stato possibile seguire il Podcast
Esecuzione del comando Non seguire più non riuscita
Behind the Insights: Ep 04 GLP-1s & Suicidal Ideation, Jessica Probst, MPH & Carl Marci, MD
-
Letto da:
-
Di:
A proposito di questo titolo
In this episode of Behind the Insights, Jessica Probst, MPH, Principal, Real-World Evidence at OM1 and Dr. Carl Marci, Chief Clinical Officer and Managing Director of Mental Health and Neuroscience at OM1, unpack a topic that’s made recent headlines and raised important questions for both clinicians and patients, suicidal ideation (SI) warnings on GLP-1 medications. While these labels have sparked concern, these experts will be discussing what the data has to say.
0:00 Intro
0:45 What inspired you to investigate potential ties between GLP-1 therapies and SI?
1:18 How did you identify instances of suicidal ideation in RWD?
2:08 Key findings
2:45 How should clinicians should manage care going forward?
3:08 Shaping future conversations
📩 Stay updated on future episodes: https://go.om1.com/l/1071043/2025-02-10/bk8151
🎯 Follow us! LinkedIn: https://www.linkedin.com/company/om1-inc./
Facebook: https://www.facebook.com/profile.php?id=6157320588666
X: https://x.com/Om1Inc
🌐 Visit our website: https://www.om1.com/
#mentalhealth #glp1 #glp1medication #suicidalideation #suicidalthoughts #ai #realworlddata #rwd #realworldevidence #rwe #clinicalresearch #pharma